SCHEMBL17147642

SCHEMBL17147642

COc1c(-c2ccccc2)cc(F)c2[nH]cc(CC(=O)N(C)C)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.39
MTNR1B P49286 3/20 0.39
BACE1 P56817 2/20 0.35
ALDH1A1 P00352 2/20 0.34
GRIN2B Q13224 1/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
FABP4 P15090 2/20 0.34
FABP5 Q01469 2/20 0.34
TUBB4A P04350 3/20 0.34
TUBB P07437 3/20 0.34
TUBA3C P0DPH7 3/20 0.34
TUBA1B P68363 3/20 0.34
TUBA4A P68366 3/20 0.34
TUBB4B P68371 3/20 0.34
TUBB3 Q13509 3/20 0.34
TUBB2A Q13885 3/20 0.34
TUBB8 Q3ZCM7 3/20 0.34
TUBA3E Q6PEY2 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1163197 0.87 MTNR1A (0.42) MTNR1AMTNR1BBACE1FABP4FABP5
SCHEMBL1163435 0.82 MTNR1A (0.40) MTNR1AMTNR1BBACE1TUBB4ATUBB
SCHEMBL1163403 0.81 MTNR1A (0.34) MTNR1AMTNR1BLMNAHSD17B10
SCHEMBL12595705 0.81 MTNR1A (0.43) MTNR1AMTNR1BBACE1ALDH1A1KDM4E
SCHEMBL12595701 0.80 MTNR1A (0.37) MTNR1AMTNR1BBACE1FABP4FABP5
SCHEMBL1163174 0.80 MTNR1A (0.40) MTNR1AMTNR1BBACE1ALDH1A1GRIN2B
SCHEMBL1163475 0.70 KDM4E (0.40) MTNR1AMTNR1BALDH1A1KDM4ELMNA
SCHEMBL1163764 0.69 FFAR1 (0.38) MTNR1AMTNR1B
SCHEMBL12559137 0.67 MTNR1A (0.38) MTNR1AMTNR1BLMNAHSD17B10
SCHEMBL1163402 0.67 HTR1A (0.48) MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150284365-A1 COMPOUNDS AND METHODS OF USE THEREOF GALENEA CORPORATION (US) 2015-10-08 US disclosed
US-20150284365-A1 COMPOUNDS AND METHODS OF USE THEREOF GALENEA CORPORATION (US) 2015-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284365-A1 COMPOUNDS AND METHODS OF USE THEREOF AANAT, HNMT, INMT MTNR1A 65/4885MTNR1B 36/4885BACE1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.